Granted Patent
B2
US 12,240,811 · App. 17/425,701 · Granted Mar 4, 2025
N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof
Inventors:
Yinsheng Zhang (Lianyungang, CN); Wangwei Ao (Lianyungang, CN); Yuan Li (Lianyungang, CN); Hui Wang (Lianyungang, CN); Hangzhou Shen (Lianyungang, CN); Jie Ni (Lianyungang, CN); Huan Zhang (Lianyungang, CN); Jie Wu (Lianyungang, CN); Li Zhang (Lianyungang, CN); Kai Cao (Lianyungang, CN); Peng Lu (Lianyungang, CN); Xushi Liu (Lianyungang, CN); Jie Wang (Lianyungang, CN); Tianxiao Zhao (Lianyungang, CN); Xingfeng Ge (Lianyungang, CN); Dandan Lu (Lianyungang, CN); Shuo Chen (Lianyungang, CN); Xueqin Ma (Lianyungang, CN); Wei Shi (Lianyungang, CN); Xiaojin Wang (Lianyungang, CN); Hongjiang Xu (Lianyungang, CN)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided is a compound of formula I or II, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and the medical uses thereof in treating diseases benefiting from the capsid protein assembly inhibitor, particularly diseases caused by hepatitis B virus infection.
Claims (4)
1. A compound of Formula I or II, a stereoisomer, a tautomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof,
2. A pharmaceutical composition comprising a compound of Formula I or II, a stereoisomer, a tautomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 .
3. A method of treating a disease caused by hepatitis B virus infection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or II, a stereoisomer, a tautomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , or a pharmaceutical composition thereof.
4. The pharmaceutical composition according to claim 2 , further comprising a pharmaceutically acceptable excipient.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 9, 2021
From: ZHANG, YINSHENG; AO, WANGWEI; LI, YUAN; WANG, HUI; SHEN, HANGZHOU; NI, JIE; ZHANG, HUAN; WU, JIE; ZHANG, LI; CAO, KAI; LU, PENG; LIU, XUSHI; WANG, JIE; ZHAO, TIANXIAO; GE, XINGFENG; LU, DANDAN; CHEN, SHUO; MA, XUEQIN; SHI, WEI; WANG, XIAOJIN; XU, HONGJIANG
To: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Reel/Frame 057118/0740 →
Priority Claims (1)
CN 201910073465.2
· Jan 25, 2019
· national
Continuity (1)
References Cited (54)
CN 101756890
· 2010
[cited by applicant]
CN 102389400
· 2012
[cited by applicant]
CN 103705478
· 2014
[cited by applicant]
CN 105431413A
· 2016
[cited by applicant]
CN 105658624A
· 2016
[cited by applicant]
CN 105980378
· 2016
[cited by applicant]
CN 105431413
· 2018
[cited by applicant]
CN 105658624
· 2019
[cited by applicant]
CN 109153640A
· 2019
[cited by applicant]
CN 109790168A
· 2019
[cited by applicant]
CN 107721895
· 2020
[cited by applicant]
RU 2470916
· 2012
[cited by applicant]
WO WO2006012642A2
· 2006
[cited by applicant]
WO WO2014184350
· 2014
[cited by applicant]
WO WO2015011281
· 2015
[cited by applicant]
WO WO2017156255
· 2017
[cited by applicant]
WO WO2017156255A1
· 2017
[cited by examiner]
WO WO2018039531
· 2018
[cited by applicant]
WO WO2018050110
· 2018
[cited by applicant]
WO WO2019165374
· 2019
[cited by applicant]
WO WO2019165374A1
· 2019
[cited by applicant]
WO WO2019185016
· 2019
[cited by applicant]
WO WO2019185016A1
· 2019
[cited by applicant]
WO WO2019241292
· 2019
[cited by applicant]
WO WO2019241292A1
· 2019
[cited by examiner]
WO WO2020151252A1
· 2020
[cited by applicant]
WO WO2020156494
· 2020
[cited by applicant]
WO WO2021058002
· 2021
[cited by applicant]
WO WO2021119081
· 2021
[cited by applicant]
B. Testa, Biochemical Pharmacology 68 (2004) 2097-2106, “Prodrug research: futile or fertile?” (Year: 2004).
[cited by examiner]
Nijampatnam et al. Current Opinion in Chemical Biology 2019, 50:73-79, Recent advances in the development of HBV capsid assembly modulators (Year: 2019).
[cited by examiner]
JP Office Action in Japanese Appln. No. 2021-542370, dated Oct. 3, 2023, 9 pages (with English translation).
[cited by applicant]
Nozaki et al., “Medicinal Drug Chemistry (Soyaku Kagaku),” 1st ed., Jul. 1, 1995, Chapter 5.2.2, pp. 98-99 (with English abstract).
[cited by applicant]
CN Office Action in Chinese Appln. No. 202080066483.9, dated Oct. 13, 2023, 10 pages (with English translation).
[cited by applicant]
He et al., “Hepatitis B virus replication mechanisms and drug targets of chronic hepatitis B,” Chinese Pharmacological Bulletin, Feb. 2015, 31(2):152-156 (with English abstract).
[cited by applicant]
Alekseyev, V.V., “Optical Isomerism and Drugs Pharmacological Activity,” Soros Educational Journal, 1998, pp. 49-55 (8 pages).
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/CN2019/108483, dated Jan. 2, 2020, 28 pages.
[cited by applicant]
International Search Report and Written Opinion in PCT/CN2020/118426, mailed on Jan. 5, 2021, 22 pages.
[cited by applicant]
Knunyants, I.L., “Chemical Encyclopedic Dictionary,” Moscow, Soviet Encyclopedia, 1983, pp. 130-131.
[cited by applicant]
Kummerer, Klaus, “Pharmaceuticals in the Environment,” Annu. Rev. Environ. Resourc., 2010, 35:57-75.
[cited by applicant]
RU Office Action in Russian Appln. No. 2021123614/04, dated Feb. 28, 2023, 27 pages (with English translation).
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/CN2020/118426, dated Mar. 15, 2022, 13 pages (with English translation).
[cited by applicant]
Brahmania, et al., “New therapeutic agents for chronic hepatitis B,” The Lancet Infectious Diseases, Jan. 13, 2016, 16(2):e10-e21.
[cited by applicant]
Greene's Protective Groups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley & Sons, Inc., chapter 2.
[cited by applicant]
Greene's Protective Groups in Organic Synthesis, 4th ed., Wuts and Greene (eds)., Apr. 2006, Chapter 2, 351 pages.
[cited by applicant]
Office Action in Eurasian Appln. No. 202092159, dated Sep. 17, 2021, 7 pages (with English translation).
[cited by applicant]
Extended European Search Report in European Appln. No. 19777163.7, dated Nov. 25, 2021, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/CN2019/108483, dated Aug. 5, 2021, 17 pages (with English translation).
[cited by applicant]